Semaglutide: The Complete Guide to Ozempic, Wegovy, and Rybelsus
Semaglutide has become one of the most discussed medications of the past decade — but the public conversation often conflates three distinct products that share an active ingredient. Ozempic is for type 2 diabetes. Wegovy is for weight management. Rybelsus is the oral version, also for diabetes. The molecule is the same; what differs are the doses, the delivery method, the approved indications, and the clinical evidence behind each.
This guide covers what semaglutide actually is, how it works (including what happens in the brain), what the major clinical trials found, what the side effect profile looks like, and what the current regulatory picture means for compounded versions.
For a broader introduction to the entire class of medications semaglutide belongs to, see our complete guide to GLP-1 receptor agonists.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic molecule designed to mimic the action of a gut hormone your body produces naturally after eating. The natural GLP-1 hormone degrades within minutes; semaglutide is engineered with a fatty acid side chain that binds to albumin in the blood, giving it a half-life of approximately one week and enabling once-weekly (or once-daily oral) dosing.
Novo Nordisk developed semaglutide as part of a long-line GLP-1 program that began with liraglutide (Victoza/Saxenda). Semaglutide is more potent and longer-acting than its predecessor, binding the GLP-1 receptor with higher affinity and producing larger effects on blood glucose and body weight at comparable doses.
How Semaglutide Works: Body and Brain
Peripheral Actions
In the pancreas, semaglutide stimulates insulin secretion in a glucose-dependent manner — meaning it only triggers insulin release when blood glucose is elevated, which explains why GLP-1 agents have a low risk of hypoglycemia when used alone. It simultaneously suppresses glucagon (the counter-regulatory hormone that raises blood sugar), slows gastric emptying (food moves out of the stomach more slowly), and increases satiety signaling from the gut to the brain via vagal afferent nerves.
The Neuroscience of Semaglutide
What separates semaglutide from earlier weight-loss medications is its reach into the central nervous system. GLP-1 receptors are expressed throughout the brain, including in regions that are not well-protected by the blood-brain barrier. Semaglutide crosses into the brainstem and hypothalamus, where it directly modulates appetite-regulating circuits — primarily the arcuate nucleus, which integrates hunger signals from leptin, ghrelin, and other hormones.
Human appetite studies suggest semaglutide affects food preference as well as total intake. [9] In a randomized crossover study by Blundell and colleagues, once-weekly semaglutide reduced overall energy intake and reduced preference for high-fat foods. That does not prove every patient will feel a dramatic change in reward signaling, but it does support the common report that food becomes easier to leave alone.
This distinction matters: earlier centrally-acting weight-loss drugs (like sibutramine, withdrawn from markets due to cardiovascular risk) worked primarily by blocking reuptake of monoamine neurotransmitters — a blunter, riskier mechanism. Semaglutide’s selectivity for GLP-1 receptors appears to offer appetite and reward modulation without the cardiovascular liability of broader monoamine interference.
Ozempic vs. Wegovy vs. Rybelsus: Same Molecule, Different Products
All three products are semaglutide. What differs is the formulation, dose, and the indication for which they carry FDA approval.
| Product | Formulation | FDA Indication | Maximum Approved Dose |
|---|---|---|---|
| Ozempic | Subcutaneous injection, once weekly | Type 2 diabetes; CV risk reduction in T2D with established CVD | 2 mg/week |
| Wegovy | Subcutaneous injection, once weekly | Chronic weight management (obesity/overweight with comorbidity) | 2.4 mg/week |
| Rybelsus | Oral tablet, once daily | Type 2 diabetes | 14 mg/day |
FDA-Approved Indications
Ozempic received initial FDA approval in December 2017 for glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. In 2020, its label was expanded to include cardiovascular risk reduction — specifically reduction of major adverse cardiovascular events (MACE: non-fatal heart attack, non-fatal stroke, or cardiovascular death) in adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial results discussed below.
Wegovy was approved in June 2021 for chronic weight management in adults with either a BMI ≥ 30 kg/m² (obesity) or BMI ≥ 27 kg/m² (overweight) with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. Its label was later updated in March 2024 to include cardiovascular risk reduction in adults with established CVD and obesity or overweight — based on SELECT trial data.
Rybelsus was approved in September 2019 for type 2 diabetes only. It is not approved for weight management. Because oral bioavailability of GLP-1 peptides is inherently low (semaglutide’s oral bioavailability is approximately 1%), Rybelsus requires strict fasting conditions at administration to maximize absorption. The effective doses are correspondingly higher (3–14 mg daily oral versus 0.5–2 mg weekly subcutaneous).
A Note on Off-Label Use
Ozempic is frequently prescribed off-label for weight loss, particularly during periods when Wegovy faced supply shortages. This is legal medical practice — clinicians can prescribe approved drugs for non-approved indications. However, the maximum Ozempic dose (2 mg/week) is lower than the Wegovy maintenance dose (2.4 mg/week), and the insurance coverage, patient assistance programs, and clinical trial data are specific to each product’s approved indication. Substituting one for the other is not straightforward from a regulatory or pharmacoeconomic standpoint.
Dosing and Titration
Both Ozempic and Wegovy are subcutaneous injections administered once weekly, on the same day each week, at any time of day with or without food. Injection sites are the abdomen, thigh, or upper arm.
Wegovy Titration Schedule
The Wegovy titration schedule was designed specifically to minimize GI side effects:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg/week |
| 5–8 | 0.5 mg/week |
| 9–12 | 1.0 mg/week |
| 13–16 | 1.7 mg/week |
| 17+ (maintenance) | 2.4 mg/week |
If a patient cannot tolerate a dose escalation due to GI side effects, clinicians can extend the current dose for an additional 4 weeks before reattempting the increase.
Ozempic Titration Schedule
Ozempic initiates at 0.25 mg/week for 4 weeks (a non-therapeutic dose intended only to reduce GI side effects), then escalates to 0.5 mg/week as the first therapeutic dose. Further escalation to 1 mg/week and 2 mg/week is available for additional glycemic control. The cardiovascular indication approved in 2020 was studied at 0.5 mg and 1 mg doses.
Rybelsus Administration
Rybelsus must be taken in the morning on an empty stomach with no more than 4 oz of plain water. No food, beverages (other than water), or other oral medications should be consumed for at least 30 minutes after taking it. This is not a suggestion — the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption enhancer in the tablet requires a low-acid, low-volume gastric environment to work. Even a full glass of water significantly reduces bioavailability.
Key Clinical Trial Results
The STEP Program (Weight Management)
The STEP (Semaglutide Treatment Effect in People with Obesity) program consisted of four pivotal phase 3 trials evaluating semaglutide 2.4 mg in adults with overweight or obesity.
STEP 1 enrolled 1,961 adults without diabetes with a BMI ≥ 30 or ≥ 27 with a weight-related comorbidity. After 68 weeks, participants receiving semaglutide lost an average of 14.9% of body weight compared to 2.4% in the placebo group — a difference of 12.4 percentage points. [1] Nearly half (69%) of semaglutide participants lost ≥ 10% of body weight, compared with 12% on placebo. This was the first weight-loss trial to approach the magnitude of effect seen with bariatric surgery in a large, randomized cohort.
STEP 4 addressed the critical question of what happens when treatment stops. Participants who lost weight on semaglutide for 20 weeks and then switched to placebo regained roughly two-thirds of their lost weight within 48 weeks, while those who continued semaglutide maintained their weight loss. [2] This finding has significant implications for how clinicians and patients think about semaglutide: it is an ongoing therapy, not a short-term intervention.
The SUSTAIN Program (Diabetes)
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trials evaluated subcutaneous semaglutide (0.5 mg and 1 mg doses) across diverse T2D populations and comparators.
SUSTAIN-6, the cardiovascular outcomes trial, enrolled 3,297 patients with T2D at high cardiovascular risk over a median follow-up of 2.1 years. Semaglutide reduced the rate of MACE by 26% relative to placebo (6.6% vs. 8.9%; HR 0.74, 95% CI 0.58–0.95). [3] This was driven primarily by reductions in non-fatal stroke and non-fatal myocardial infarction.
Across the early SUSTAIN program, semaglutide consistently improved A1C and body weight in type 2 diabetes populations. [6]
The SELECT Trial (Cardiovascular in Non-Diabetic Patients)
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark trial that enrolled over 17,600 adults aged ≥ 45 with a BMI ≥ 27 and established cardiovascular disease — but without type 2 diabetes. This was the first cardiovascular outcomes trial for any GLP-1 agent in a purely non-diabetic population.
Over a mean follow-up of 34.2 months, semaglutide 2.4 mg/week reduced MACE by 20% compared to placebo (6.5% vs. 8.0%; HR 0.80, 95% CI 0.72–0.90). [4] The mechanism for this cardiovascular benefit in the absence of glycemic effects is an active area of investigation — candidates include direct anti-inflammatory effects on atherosclerotic plaques, improvements in blood pressure and lipids, and reduced cardiac fat. The SELECT data led to the March 2024 label update for Wegovy to include this cardiovascular indication.
Side Effect Profile
Semaglutide’s side effect profile is described in detail in our dedicated GLP-1 side effects guide. The most relevant points for semaglutide specifically:
Gastrointestinal effects are the most common reason for dose adjustment or discontinuation. Nausea affects approximately 44% of Wegovy participants at some point during treatment (vs. 16% placebo in STEP 1), with vomiting in 24% and diarrhea in 30%. The titration schedule was specifically designed to minimize these effects — they peak during escalation phases and typically improve once stable dosing is reached.
Serious but rare risks include:
- Pancreatitis: A class-wide warning exists based on post-marketing reports; the STEP and SUSTAIN trials did not show a statistically significant increase. Patients with a history of pancreatitis should discuss this risk with their clinician.
- Thyroid C-cell tumors: A contraindication exists for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). The signal originated from rodent studies; no human evidence currently confirms an elevated MTC risk.
- Diabetic retinopathy: SUSTAIN-6 observed a higher rate of diabetic retinopathy complications in the semaglutide group (3.0% vs. 1.8%). This is thought to reflect rapid improvement in glycemic control — a paradoxical worsening seen with any intensive glucose-lowering regimen in patients with pre-existing retinopathy. Ophthalmologic monitoring is recommended for T2D patients with known retinopathy starting semaglutide.
- Gallbladder disease: GLP-1 agents slow gallbladder motility, increasing the risk of gallstones. Across the STEP program, cholelithiasis was reported in approximately 2.5% of semaglutide patients vs. 1.2% placebo.
Lean muscle mass considerations: As with all methods of significant weight loss, a portion of weight lost on semaglutide includes lean mass (estimated at 25–40% of total weight lost in clinical trials). This proportion is similar to dietary restriction alone. Resistance exercise and adequate protein intake are the primary strategies for preserving muscle during treatment.
Cost and Insurance Coverage
Semaglutide products carry high list prices in the United States — Wegovy’s list price has been approximately $1,349/month, and Ozempic approximately $968/month, though actual out-of-pocket costs depend heavily on insurance coverage and available savings programs.
Insurance coverage for Wegovy for weight management remains inconsistent. Many commercial plans still exclude or restrict anti-obesity medications, while Ozempic is usually easier to cover when the diagnosis is type 2 diabetes. The SELECT cardiovascular indication may broaden access for some patients with established cardiovascular disease, but coverage still depends on plan rules.
Novo Nordisk offers a savings card program (Novo Nordisk Patient Assistance Program) for eligible commercially-insured patients. Patients without insurance or with inadequate coverage should discuss options with their healthcare provider.
Compounded Semaglutide: FDA Position and Safety Concerns
From 2022 through early 2024, widespread shortages of both Ozempic and Wegovy allowed pharmacies operating under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act to compound semaglutide products — a legal exception that applies only when an FDA-approved drug is on the shortage list.
The FDA raised specific concerns during this period about the safety of compounded semaglutide: [8]
- Salt form vs. base molecule: Some compounders used semaglutide sodium or semaglutide acetate rather than semaglutide base. These salt forms are not the same as the active pharmaceutical ingredient in approved products and have not been separately evaluated for safety or efficacy.
- Dosing accuracy: Without the quality controls required of FDA-approved manufacturers, dose consistency in compounded products cannot be verified.
- Contamination risk: The FDA received adverse event reports linked to compounded semaglutide, including reports of hospitalizations.
Current regulatory status (as of March 2026): The FDA removed Ozempic from the drug shortage list in February 2024 and Wegovy in May 2024. This ended the legal basis for shortage-exemption compounding of semaglutide under 503A for most patients. 503B outsourcing facilities were given additional time to comply but are now also prohibited from producing copies. Patients who obtained semaglutide through compounding pharmacies should transition to FDA-approved products.
The bottom line: the FDA’s position is that compounded semaglutide is not FDA-approved and carries specific safety concerns, especially now that the shortage-era exception has narrowed. This is not a statement that all compounding is illegitimate. It is a warning that a compounded copy should not be treated as interchangeable with the approved products without a strong patient-specific reason.
Who Is a Candidate for Semaglutide?
Semaglutide is FDA-approved for:
- Adults with type 2 diabetes needing additional glycemic control (Ozempic or Rybelsus)
- Adults with established CVD and T2D seeking cardiovascular risk reduction (Ozempic)
- Adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with a weight-related comorbidity (Wegovy)
- Adults with established CVD and obesity/overweight seeking cardiovascular risk reduction (Wegovy)
Absolute contraindications include:
- Personal or family history of medullary thyroid carcinoma or MEN2
- Pregnancy (contraindicated; should be discontinued ≥ 2 months before planned conception)
- Known hypersensitivity to semaglutide or excipients
Relative considerations that require clinical discussion include prior pancreatitis history, diabetic retinopathy, gallbladder disease history, and severe gastrointestinal conditions.
Semaglutide should be prescribed and monitored by a licensed healthcare provider. The clinical decisions around which product, what starting dose, and how to manage side effects require individual evaluation that no article can replace.
Summary
Semaglutide is a well-studied GLP-1 receptor agonist with robust clinical evidence across glycemic control, weight management, and cardiovascular risk reduction. Its mechanism of action in the brain — particularly in appetite regulation and reward pathways — helps explain why its effects on eating behavior can feel different from simple calorie restriction. The three branded products (Ozempic, Wegovy, Rybelsus) are not interchangeable: they carry different approvals, doses, and evidence bases.
For most patients considering semaglutide, the critical practical questions are insurance coverage, which formulation aligns with their FDA-indicated condition, and how to manage the GI titration period. For deeper guidance on the side effects and how to manage them, see our GLP-1 side effects guide. For a head-to-head comparison of semaglutide with tirzepatide, see Tirzepatide vs. Semaglutide: Which Is More Effective?.
Frequently Asked Questions
- What is the difference between Ozempic and Wegovy?
- Both Ozempic and Wegovy contain the same active molecule — semaglutide — but are FDA-approved for different indications at different doses. Ozempic (approved 2017) is indicated for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established CVD; its doses range from 0.5mg to 2mg weekly. Wegovy (approved 2021) is indicated for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition; its maintenance dose is 2.4mg weekly, higher than any Ozempic dose. Using Ozempic off-label for weight loss is common but not the same as the FDA-approved Wegovy regimen.
- How long does it take for semaglutide to work?
- Blood sugar improvements in T2D patients typically appear within the first 4 weeks. Meaningful weight loss usually becomes noticeable between weeks 8 and 16, though the full therapeutic effect builds over the entire 68-week titration and treatment period used in the STEP trials. The titration schedule — which starts at 0.25mg and increases every 4 weeks — exists primarily to reduce side effects, not because lower doses are ineffective; the 2.4mg maintenance dose is where most of the weight loss efficacy resides.
- Can I take Rybelsus instead of an injection?
- Rybelsus is the only oral formulation of semaglutide, approved for type 2 diabetes only — not for weight management. It requires strict administration: on an empty stomach with no more than 4 oz of water, at least 30 minutes before the first food, drink, or other medication of the day. Head-to-head data from PIONEER 4 showed oral semaglutide 14mg had similar A1C reductions to subcutaneous semaglutide 0.5mg, though absorption can be variable. For weight management, only the subcutaneous injection (Wegovy) is FDA-approved.
- Is compounded semaglutide safe?
- The FDA has raised specific safety concerns about compounded semaglutide. Some compounders used semaglutide sodium or semaglutide acetate salt forms rather than the base molecule used in approved products — these are not pharmaceutically equivalent and have not been evaluated for safety or efficacy. As of early 2024, the FDA has resolved the semaglutide shortage designation for both Ozempic and Wegovy, which means compounding under the shortage exemption is no longer permitted. Patients should obtain semaglutide only through licensed pharmacies dispensing FDA-approved products.
- What happens if I stop taking semaglutide?
- The STEP 4 trial provides the clearest evidence: participants who stopped semaglutide after 20 weeks and switched to placebo regained approximately two-thirds of their prior weight loss within 48 weeks, while those who continued treatment maintained their loss. Blood glucose and cardiovascular risk markers also returned toward baseline after discontinuation. This reflects the underlying biology — semaglutide suppresses appetite and regulates blood sugar while it's active, but does not permanently reset the body's weight-regulatory systems.
Last reviewed: March 28, 2026
Sign up for our newsletter to receive evidence-based updates on GLP-1 medications as new trial data emerges.
